



HAL
open science

Association Between Lack of Blinding and Mortality Results in Critical Care Randomized Controlled Trials

Guillaume L Martin, Théo Trioux, Stéphane Gaudry, Florence Tubach, David
Hajage, Agnès Dechartres

► **To cite this version:**

Guillaume L Martin, Théo Trioux, Stéphane Gaudry, Florence Tubach, David Hajage, et al.. Association Between Lack of Blinding and Mortality Results in Critical Care Randomized Controlled Trials. *Critical Care Medicine*, 2021, Publish Ahead of Print, pp.1800-1811. 10.1097/CCM.0000000000005065 . hal-03217678

HAL Id: hal-03217678

<https://hal.sorbonne-universite.fr/hal-03217678>

Submitted on 5 May 2021

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Association between lack of blinding and mortality results in critical-care randomized controlled trials: a meta-epidemiological study

Guillaume L Martin, M.D.¹, Théo Trioux, M.D.¹, Stéphane Gaudry M.D., Ph.D.^{2,3}, Florence Tubach M.D., Ph.D.¹, David Hajage M.D., Ph.D.¹, Agnès Dechartres, M.D., Ph.D.¹

¹ Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, AP-HP.

Sorbonne Université, Hôpital Pitié Salpêtrière, Département de Santé Publique, F75013, Paris, France

² Département de réanimation médico-chirurgicale, APHP, Hôpital Avicenne, UFR SMBH, Université

Sorbonne Paris Nord, Bobigny, France

³ Common and Rare Kidney Diseases, Sorbonne Université, INSERM, UMR-S 1155, Paris, France

Correspondence to: Agnès Dechartres, M.D., PhD,

Department of Public Health

Hôpital Pitié-Salpêtrière,

47-83, boulevard de l'Hôpital, 75013 Paris, France

E-mail: adechartres@gmail.com; agnes.dechartres@aphp.fr

Article word count: 3000

Financial support: no external funding source.

Keywords: bias, blinding, critical care, research design, randomized controlled trials, meta-analysis, mortality, meta-epidemiological study

ABSTRACT (268 words)

Objective: To investigate whether intervention effect estimates for mortality differ between blinded and non-blinded randomized controlled trials (RCTs) conducted in critical care.

Design: Meta-epidemiological study, comparing effect estimates between blinded and non-blinded RCTs for the same research question.

Data sources: Systematic reviews and meta-analyses of RCTs evaluating a therapeutic intervention on mortality in critical care, published between January 2009 and March 2019 in high impact factor general medical or critical-care journals and by Cochrane.

Data extraction: For each RCT included in eligible meta-analyses, we evaluated whether the trial was blinded (ie, double-blinded and/or reporting adequate methods) or not (ie, open-label, single-blinded or unclear). We collected risk of bias evaluated by the review authors and extracted trial results.

Data synthesis: Within each meta-analysis, we compared intervention effect estimates between blinded and non-blinded RCTs by using a ratio of odds ratio (ROR) (ROR<1 indicates larger estimates in non-blinded than blinded RCTs). We then combined RORs across meta-analyses to obtain the average relative difference between non-blinded and blinded trials.

Results: Among 467 RCTs included in 36 meta-analyses, 267 (57%) were considered blinded and 200 (43%) non-blinded. Intervention effect estimates were statistically significantly larger in non-blinded than blinded trials (combined ROR 0.91 [95% CI 0.84–0.99]). We found no heterogeneity across meta-analyses ($p=0.72$, $I^2=0\%$, $\tau^2=0$). Sensitivity analyses adjusting the main analysis on risk of bias items yielded consistent results.

Conclusions: Intervention effect estimates of mortality were slightly larger in non-blinded than blinded RCTs conducted in critical care, but confounding cannot be excluded. Blinding of both patients and personnel is important to consider when possible in critical-care trials, even when evaluating mortality.

Trials registration: Not applicable. This is a research-on-research study.

INTRODUCTION

Mortality is one of the most important outcomes to evaluate in clinical trials and considered one of the most objective because not subject to interpretation. Most meta-epidemiological studies showed no difference in intervention effect estimates between blinded and non-blinded trials evaluating mortality, whereas for subjective outcomes, effects were significantly larger in non-blinded trials(1–3). A more recent study suggested that the situation may not be simple(4), highlighting the need for additional methodological research across a variety of contexts(5).

In critical care, mortality is a peculiar outcome because physicians often have to limit life-sustaining treatments to preserve patient dignity in end-of-life care, which is nowadays the most common death scenario in many intensive care units (ICUs)(6–11). Physicians also have access to life-support techniques to prolong life via artificial cardiac and respiratory assistance(12,13). Without blinding, belief in a favourable effect of novel experimental interventions might influence physicians, even unconsciously, when making these decisions, which may affect the timing of death(14,15). This situation could lead to biased intervention effect estimates on mortality if such decisions differ between randomisation arms. This issue might be of particular importance in these times of pandemic : many prominent COVID-19 trials were open-label(16,17). The association between lack of blinding and mortality estimates in critical-care clinical trials was explored in 2 studies(18,19), with inconsistent results. These studies compared effect estimates between blinded and non-blinded trials mixing different research questions, which might bias their results. Meta-epidemiological studies are the reference method to identify bias(20) as they evaluate within meta-analyses of the same intervention how a trial characteristic is associated with intervention effect.

In this study, we investigated whether intervention effect estimates for mortality differ between blinded and non-blinded randomized controlled trials (RCTs) conducted in critical care.

METHODS

Study design

We performed a meta-epidemiological study based on a sample of meta-analyses evaluating the effect of a therapeutic intervention on mortality in critical care.

Data sources

In April 2019, we conducted a search on PubMed using an algorithm combining MeSH terms and free-text words to identify systematic reviews and meta-analyses of RCTs conducted in critical care (**Supplemental Digital Content**).

We restricted the search to articles published from January 2009 to March 2019 to rely on recent systematic reviews. We also restricted the search to the five highest impact factor (IF) general medical journals according to the *Journal of Citation Reports* (*The New England Journal of Medicine*, *The Lancet*, *The Journal of the American Medical Association*, *The BMJ*, *Annals of Internal Medicine*), the *Cochrane Database of Systematic Reviews* and the six highest IF critical-care journals (*Lancet Respiratory Medicine*, *American Journal of Respiratory and Critical Care Medicine*, *Intensive Care Medicine*, *Chest*, *Critical Care Medicine*, *Critical Care*).

Identification of eligible meta-analyses

We screened titles and abstracts, and full texts whenever necessary, to identify reports of systematic reviews with meta-analyses of RCTs conducted in critical care that assessed an experimental intervention against placebo or standard-care and including mortality as an outcome. We chose not to include comparisons between experimental interventions because of the uncertainty in the direction of bias. We focused on adult populations and did not include reviews concerning paediatric populations because the issue of end-of-life may be more complex. Because some reviews may include both adult and paediatric trials, we selected them if they included a maximum 20% of paediatric RCTs per meta-analysis. We then identified reviews with meta-analyses of mortality

including ≥ 3 RCTs (3 is the minimum to conduct a meta-epidemiological analysis) and evaluated blinding.

Two reviewers (GLM and TT) independently selected reviews with disagreements resolved by discussion, referring to a third opinion (AD) when necessary.

Evaluation of blinding in RCTs

We searched the full-text report of each RCT included in selected meta-analyses. We first evaluated the article presenting the main findings, and if information on blinding was not reported or unclear, we searched for additional references such as the protocol or trial registration. We considered an RCT blinded if it was described as a double-blinded trial (defined as unknown intervention by both patients and personnel) and/or mentioned the use of adequate methods for double-blinding (eg, matched placebo). We considered an RCT non-blinded if it was described as a single-blind or open-label trial, had distinguishable interventions or no information was reported.

Two reviewers (GLM and TT) independently evaluated blinding with disagreements resolved by discussion, referring to a third opinion (AD) when necessary.

Final selection of meta-analyses and exclusion of overlaps

To conduct the meta-epidemiological analysis, we selected only meta-analyses including at least one blinded and one non-blinded trial. When an individual systematic review had multiple eligible meta-analyses because of different time points evaluated, we selected the meta-analysis evaluating short-term (≤ 31 days) mortality and in case of several such meta-analyses, the one including the highest number of RCTs. If short-term mortality was not available, we included the meta-analysis with the highest number of RCTs. We chose short-term mortality as the preferred outcome because it was the most frequently reported in critical-care RCTs(21), but planned to conduct a subgroup analysis for different outcome timing (see below).

Finally, we identified and removed overlapping meta-analyses, defined as those sharing ≥ 3 RCTs. In case of overlap, we kept the meta-analysis with the highest number of RCTs.

Data extraction

One reviewer (GLM) extracted data using extraction forms, referring to a second opinion (AD) when necessary. Another reviewer (TT) independently extracted data for half of the meta-analyses chosen at random for quality insurance. We collected the following data on meta-analyses: general characteristics, medical condition, interventions evaluated, time-point for mortality and the following data for each RCT: general characteristics, blinding as described above, risk of bias (RoB) and results (numbers of events and of patients analysed in each group).

Statistical methods

Estimation of intervention effects within meta-analyses

We estimated the intervention effects within each meta-analysis as odds ratios (OR) and 95% confidence intervals (CIs). Outcomes were recoded when necessary so that an $OR < 1$ indicated a beneficial effect of the experimental intervention on mortality. We used random-effects models to combine intervention effects across RCTs within each meta-analysis. RCTs with no event or all events in both groups did not contribute to the analysis. When necessary, we used a continuity-correction to deal with zero cell-counts in one arm(22). Heterogeneity across RCTs was assessed with the Cochran Q chi-square test, I^2 statistic, and between-study variance τ^2 .

Meta-epidemiological analysis

Using a two-step approach(23), we first calculated, within each meta-analysis, the ratio of ORs (ROR) — the ratio of the intervention-effect OR in non-blinded RCTs to the OR in blinded RCTs by using a random-effects meta-regression model. An $ROR < 1$ indicates larger intervention effect estimates for mortality for non-blinded than blinded trials. Second, we calculated a combined ROR across all meta-analyses by using a random-effects meta-analysis model. This combined ROR

represents the average relative difference between non-blinded and blinded trials across included meta-analyses. Heterogeneity across meta-analyses was quantified with the Cochran Q chi-square test, I^2 statistic, and between-meta-analysis variance τ^2 .

Subgroup, sensitivity and secondary analyses

As previously mentioned, a pre-specified subgroup analysis concerned the timing of the mortality outcome (*short-term*, defined as in ICU or ≤ 31 days, vs *long-term*, defined as >31 days, in-hospital, overall or longest follow-up). We used an interaction test to assess whether the combined ROR varied between subgroups.

To control for confounding, sensitivity analyses were performed by adjusting the meta-regression models for sample size and each item of the RoB tool using the review author's evaluation (*high or unclear risk vs low risk*), except the item "blinding of participants and personnel" because of collinearity with our assessment of blinding. Meta-analyses had to include ≥ 4 RCTs to contribute to the sensitivity analyses (accounting for the additional co-variable(24)).

As a secondary analysis, with the same sample, we performed a meta-epidemiological analysis using the review authors' evaluation of RoB for the item "blinding of participants and personnel", instead of our manual assessment of blinding.

All analyses involved use of R v3.6.0 (R Foundation for Statistical Computing, Vienna, Austria).

RESULTS

Selection and general characteristics

Among 720 references identified, 186 reports of systematic reviews were selected, with their relevant meta-analyses assessed for eligibility. We found 84 eligible meta-analyses including at least 3 RCTs with one blinded and one non-blinded trial. Among these, 47 meta-analyses overlapped and 1 had unusable data (computed mean-differences, without additional data available), so 36 meta-analyses remained in our sample. **Figure 1** lists reasons for exclusion.

Table 1 presents detailed characteristics of the included meta-analyses. Briefly, 20 meta-analyses were published in critical-care journals, 2 in general medical journals and 14 by Cochrane. Most meta-analyses evaluated pharmacological interventions (97.2%). They covered a wide range of critical-care pathologies. In most meta-analyses (75%), the authors used the Cochrane tool to assess RoB. Different time-points were evaluated for mortality, with short-term time-points evaluated in 17 meta-analyses and longer-term time-points in 19 meta-analyses. Only one meta-analysis showed substantial heterogeneity ($I^2 \geq 50\%$) (**Supplemental Digital Content – Table 1**). The meta-analyses included 467 RCTs (total of 116,678 patients) contributing to the analysis. The median number of RCTs per meta-analysis was 11.5 (range 3 to 36).

Comparison of blinded and non-blinded trials

Table 2 presents characteristics of blinded and non-blinded trials. Among the 467 RCTs included, 267 (57%) were blinded and 200 (43%) non-blinded. The median sample size was smaller in non-blinded than blinded trials (60 [interquartile range (IQR) 34.8–104.8] vs 96 [IQR 45.5–249]). Non-blinded RCTs were less frequently judged as low RoB than were blinded RCTs for random sequence generation (45.5% vs 61.0%) and allocation concealment (39.5% vs 55.4%). For RoB related to blinding of participants and personnel, 15.5% of non-blinded RCTs were judged at low risk by review authors, and 6% of blinded RCTs were judged at high or unclear risk.

Non-blinded and blinded RCTs did not differ in year of publication: 145 (72.5%) and 203 (76%), respectively, had results published after year 2000. The median publication year was 2007 for both groups.

Comparison of intervention effect estimates between blinded and non-blinded trials

Figure 2 shows the difference in intervention effect estimates for mortality between blinded and non-blinded trials. Intervention effect estimates were significantly larger for non-blinded than blinded trials, with a combined ROR of 0.91 (95% CI 0.84–0.99). We found no heterogeneity across meta-analyses ($p=0.70$, $I^2=0\%$, $\tau^2=0$).

Subgroup, sensitivity and secondary analyses

On subgroup analysis, for the 17 meta-analyses reporting short-term mortality, the combined ROR was 0.88 (95% CI 0.79–0.99) with no heterogeneity (**Figure 2**). For the 19 meta-analyses reporting longer-term mortality, the combined ROR was 0.94 (95% CI 0.83–1.10), with no heterogeneity. The interaction test was not statistically significant ($p=0.44$).

Figure 3 shows the results of the sensitivity analyses. For adjustments on random sequence generation, results were consistent with the primary analysis. For the other items of the RoB tool and sample size, the orientation of the adjusted ROR remained in favour of non-blinded trials, although no longer significant.

Supplemental Digital Content - Figure 1 shows the results of the secondary analysis. Among the 32 meta-analysis eligible for this analysis, the combined ROR was 0.93, consistent with the primary analysis, although no longer significant (95% CI 0.83–1.03).

DISCUSSION

In this meta-epidemiological study comparing intervention effect estimates for mortality between blinded and non-blinded RCTs in critical care, we analysed 36 meta-analyses, including 467 RCTs. The intervention effect estimate for mortality was statistically significantly larger for non-blinded than blinded RCTs, with a combined ROR of 0.91.

Our selection of meta-analyses covered most eligible critical-care topics, providing a generalizable sample of the discipline. We selected recent meta-analyses published in high IF general medical and critical-care journals or published by Cochrane, because these are more likely to be well reported(25,26) and concern subjects that are important to a large readership. In addition, we used a meta-epidemiological approach, which has become the reference method to identify bias(20).

Our study has some limitations. First, regarding selection, some meta-analyses might have been missed with our search strategy. Nevertheless, our aim was not to be exhaustive but to obtain a representative sample of meta-analyses, and we see no reason why this could have biased our results. Second, because blinding is difficult to ensure for non-pharmacological interventions, our sample included mostly pharmacological interventions. Another limitation is related to meta-confounding(27). Although we tried to limit it with sensitivity analyses adjusted for each RoB item and sample size, meta-confounding cannot be excluded. We only evaluated blinding in individual RCTs and did not re-evaluate RoB for the other items. There may be discrepancies between RoB definitions, tools, or authors' judgments across meta-analyses. Finally, because this is the first critical-care focused meta-epidemiological study on this subject, results should be confirmed in future studies.

Lack of blinding has for long been considered a potential source of bias in RCTs because knowing which intervention is received by the patient might affect follow-up and outcome assessment. Many meta-epidemiological studies(1–3,28–31) assessed blinding, however evidence was not consistent across them. Recent studies(1–3) analysed the effect of blinding according to the type of outcome: lack of blinding was significantly associated with larger intervention estimates in trials

with subjective outcomes. When the outcome was mortality or objectively assessed, blinded and non-blinded trials did not differ. Accordingly, the previous version of the Cochrane RoB tool(32), published in 2011, indicated that bias related to blinding could be judged at low risk in non-blinded studies if knowledge of the assigned intervention was not likely to affect the outcome, such as mortality. This definition may explain the discrepancies between our evaluation of blinding and assessment by review authors. Our secondary analysis considering assessment related to blinding by review authors was consistent though, but the difference was slightly lower. Anthon et al.(18) previously had a similar approach comparing RCTs in critical-care Cochrane reviews, using the review authors' assessment for blinding. They found no evidence that RCTs judged at high or unclear risk for blinding affected intervention estimates for mortality, but they did not use a meta-epidemiological approach and included fewer studies. Many non-blinded trials might also have been judged at low risk, considering the previous version of the Cochrane RoB tool(32). The tool was revised in 2019(33). In the new version, any deviations arising from lack of blinding, regardless of their supposed impact, should be judged “some concerns” or “high risk” of bias. Another study assessed the association of blinding with mortality in critical care. Baiardo et al.(19) selected critical-care RCTs published between 2000 and 2015 with statistically significant results for mortality, and calculated the median number-needed-to-treat for blinded and non-blinded RCTs. The authors found that the number-needed-to-treat was higher for blinded than non-blinded RCTs, but they did not use a meta-epidemiological approach and compared RCTs of different topics.

We found that non-blinded trials seem to favour intervention effect for mortality, with a ROR of 0.91. Several reasons might explain this result. First, it may be explained by the higher RoB associated with non-blinded trials, known to exaggerate intervention effect estimates(28,34–37). Non-blinded trials in our study also had a smaller sample size than blinded trials, and our sensitivity analysis adjusted on sample size largely reduced the difference. This suggests that our results may be explained by small-study effect(38–41), the tendency for small studies to show larger intervention effect than larger studies within meta-analyses, which may be explained by publication and other

reporting bias but also differences in methodological quality (including blinding) between small and large trials. Another possible explanation may be related to differences in end-of-life or life-support practices and their timing between groups in non-blinded RCTs. A belief in a favourable effect of novel experimental interventions might influence physicians, even unconsciously, in the timing of such decisions. This situation might be particularly true in RCTs evaluating mortality in the short-term, which are the most common in critical care(21). In such trials, different timing of end-of-life decisions could let some patients cross the mortality evaluation time-point and thus impact intervention estimates. Compatible with this hypothesis, our subgroup analysis showed larger difference between non-blinded and blinded trials evaluating mortality on the short-term than on the long-term, although the interaction was not significant, possibly due to a lack of power. This should be explored in further studies.

Overall, the pooled ROR of 0.91 seems small, but is similar to that observed for inadequate or unclear random sequence generation(2,42). Such small difference may have an impact on trial results and conclusions when the fragility index is high, which is frequent in critical care(43). Our results provide an important argument for blinding in critical-care trials evaluating mortality. Blinding may be difficult to achieve though: it is costly, can discourage recruitment and continuation in clinical trials(4,44), or can simply be unfeasible in critical-care settings. Our findings showing an association between lack of blinding and higher intervention estimates for mortality suggest open-label critical-care trials should be considered at high RoB, but does not mean their conclusions are inevitably wrong. A more nuanced approach might be needed to improve the reliability of their results. First, reporting longer-term mortality as the preferable primary outcome should be encouraged(45): it is clinically more relevant and seems less influenced by lack of blinding. Second, the reporting of end-of-life decisions in short-term trials should be improved. Recent systematic reviews of critical-care trials(15,46) found that only 9-18.5% reported end-of-life decisions. The Consolidated Standards of Reporting Trials (CONSORT) statement, updated in 2010(47) and adopted by most medical journals, does not require reporting these decisions. In light of our findings, we further the call by Messika et

al.(15), asking for a mandated report in critical-care trials of numbers and timing of end-of-life and life-support decisions. Future studies could then investigate whether an imbalance of practices exists between groups in non-blinded critical-care RCTs and if these could bias the results.

CONCLUSION

In this meta-epidemiological study, we found statistically significantly larger intervention effects for mortality in non-blinded than blinded trials in critical care, but confounding cannot be excluded. Our results suggest that double-blinding is important to consider when possible in critical-care trials, even when evaluating mortality. If not possible, the use of longer-term mortality as primary outcome and the better reporting of end-of-life and life-support decisions should be considered.

Ethics approval: Not applicable. This is a research-on-research study.

Availability of data and materials: The datasets, code and analysis are available from the corresponding author on request and on the following link:

https://github.com/GuillaumeMartinMD/blinding_mortality_ICU.

Competing interests: The authors declare that they have no competing interests.

Author's contribution:

GLM participated in the design of the study, selection and acquisition of data, conducted statistical analyses, interpreted the data and wrote the manuscript.

TT was involved in the selection and acquisition of data and critically reviewed the manuscript.

SG participated in the interpretation of data and critically reviewed the manuscript.

FT participated in the interpretation of data and critically reviewed the manuscript.

DH participated in the interpretation of data and critically reviewed the manuscript.

AD participated in the design of the study, interpretation of data and writing of the manuscript. She is the guarantor. She had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Acknowledgments: Laura Smales, BioMedEditing, for English editing of the manuscript.

REFERENCES

1. Wood L, Egger M, Gluud LL, Schulz KF, Jüni P, Altman DG, et al. Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study. *BMJ*. 2008 Mar 13;336(7644):601–5.
2. Savović J, Jones HE, Altman DG, Harris RJ, Jüni P, Pildal J, et al. Influence of reported study design characteristics on intervention effect estimates from randomized, controlled trials. *Ann Intern Med*. 2012 Sep 18;157(6):429–38.
3. Savovic J, Turner RM, Mawdsley D, Jones HE, Beynon R, Higgins JPT, et al. Association Between Risk-of-Bias Assessments and Results of Randomized Trials in Cochrane Reviews: The ROBES Meta-Epidemiologic Study. *Am J Epidemiol*. 2018 01;187(5):1113–22.
4. Moustgaard H, Clayton GL, Jones HE, Boutron I, Jørgensen L, Laursen DLT, et al. Impact of blinding on estimated treatment effects in randomised clinical trials: meta-epidemiological study. *BMJ*. 2020 21;368:l6802.
5. Drucker A, Chan A-W. Blindsided: challenging the dogma of masking in clinical trials. *BMJ*. 2020 Jan 21;368:m229.
6. Azoulay E, Metnitz B, Sprung CL, Timsit J-F, Lemaire F, Bauer P, et al. End-of-life practices in 282 intensive care units: data from the SAPS 3 database. *Intensive Care Med*. 2009 Apr;35(4):623–30.
7. Sprung CL, Cohen SL, Sjøkvist P, Baras M, Bulow H-H, Hovilehto S, et al. End-of-life practices in European intensive care units: the Ethicus Study. *JAMA*. 2003 Aug 13;290(6):790–7.
8. Ferrand E, Robert R, Ingrand P, Lemaire F, French LATAREA Group. Withholding and withdrawal of life support in intensive-care units in France: a prospective survey. French LATAREA Group. *Lancet Lond Engl*. 2001 Jan 6;357(9249):9–14.
9. Curtis JR, Vincent J-L. Ethics and end-of-life care for adults in the intensive care unit. *Lancet Lond Engl*. 2010 Oct 16;376(9749):1347–53.
10. Hua M, Halpern SD, Gabler NB, Wunsch H. Effect of ICU strain on timing of limitations in life-sustaining therapy and on death. *Intensive Care Med*. 2016 Jun;42(6):987–94.
11. Cook D, Rucker G. Dying with dignity in the intensive care unit. *N Engl J Med*. 2014 Jun 26;370(26):2506–14.
12. Karagiannidis C, Brodie D, Strassmann S, Stoelben E, Philipp A, Bein T, et al. Extracorporeal membrane oxygenation: evolving epidemiology and mortality. *Intensive Care Med*. 2016 May;42(5):889–96.
13. Combes A, Hajage D, Capellier G, Demoule A, Lavoué S, Guervilly C, et al. Extracorporeal Membrane Oxygenation for Severe Acute Respiratory Distress Syndrome. *N Engl J Med*. 2018 May 24;378(21):1965–75.
14. Psaty BM, Prentice RL. Minimizing Bias in Randomized Trials: The Importance of Blinding. *JAMA*. 2010 Aug 18;304(7):793–4.

15. Messika J, Gaudry S, Tubach F, Guillo S, Dreyfuss D, Hajage D, et al. Underreporting of End-of-Life Decisions in Critical Care Trials: A Call to Modify the Consolidated Standards of Reporting Trials Statement. *Am J Respir Crit Care Med*. 2018 Jan 15;197(2):263–6.
16. RECOVERY Collaborative Group, Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, et al. Dexamethasone in Hospitalized Patients with Covid-19 - Preliminary Report. *N Engl J Med*. 2020 Jul 17;
17. Angus DC, Derde L, Al-Beidh F, Annane D, Arabi Y, Beane A, et al. Effect of Hydrocortisone on Mortality and Organ Support in Patients With Severe COVID-19: The REMAP-CAP COVID-19 Corticosteroid Domain Randomized Clinical Trial. *JAMA*. 2020 Oct 6;324(13):1317–29.
18. Anthon CT, Granholm A, Perner A, Laake JH, Møller MH. No firm evidence that lack of blinding affects estimates of mortality in randomized clinical trials of intensive care interventions: a systematic review and meta-analysis. *J Clin Epidemiol*. 2018 Aug;100:71–81.
19. Baiardo Redaelli M, Belletti A, Monti G, Lembo R, Ortalda A, Landoni G, et al. The impact of non-blinding in critical care medicine trials. *J Crit Care*. 2018 Dec 1;48:414–7.
20. Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). *Cochrane Handbook for Systematic Reviews of Interventions* version 6.0 (updated July 2019) [Internet]. Cochrane. 2019 [cited 2019 Oct 21]. Available from: www.training.cochrane.org/handbook
21. Gaudry S, Messika J, Ricard J-D, Guillo S, Pasquet B, Dubief E, et al. Patient-important outcomes in randomized controlled trials in critically ill patients: a systematic review. *Ann Intensive Care*. 2017 Dec;7(1):28.
22. Sweeting MJ, Sutton AJ, Lambert PC. What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data. *Stat Med*. 2004 May 15;23(9):1351–75.
23. Sterne JAC, Jüni P, Schulz KF, Altman DG, Bartlett C, Egger M. Statistical methods for assessing the influence of study characteristics on treatment effects in “meta-epidemiological” research. *Stat Med*. 2002 Jun 15;21(11):1513–24.
24. Dechartres A, Atal I, Riveros C, Meerpohl J, Ravaud P. Association Between Publication Characteristics and Treatment Effect Estimates: A Meta-epidemiologic Study. *Ann Intern Med*. 2018 18;169(6):385–93.
25. Dechartres A, Trinquart L, Atal I, Moher D, Dickersin K, Boutron I, et al. Evolution of poor reporting and inadequate methods over time in 20 920 randomised controlled trials included in Cochrane reviews: research on research study. *BMJ*. 2017 Jun 8;357:j2490.
26. Lee KP, Schotland M, Bacchetti P, Bero LA. Association of journal quality indicators with methodological quality of clinical research articles. *JAMA*. 2002 Jun 5;287(21):2805–8.
27. Bae J-M. Meta-epidemiology. *Epidemiol Health* [Internet]. 2014 Sep 25 [cited 2020 Jan 2];36. Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4220603/>
28. Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. *JAMA*. 1995 Feb 1;273(5):408–12.

29. Balk EM, Bonis PAL, Moskowitz H, Schmid CH, Ioannidis JPA, Wang C, et al. Correlation of quality measures with estimates of treatment effect in meta-analyses of randomized controlled trials. *JAMA*. 2002 Jun 12;287(22):2973–82.
30. Bialy L, Vandermeer B, Lacaze-Masmonteil T, Dryden DM, Hartling L. A meta-epidemiological study to examine the association between bias and treatment effects in neonatal trials. *Evid-Based Child Health Cochrane Rev J*. 2014 Dec;9(4):1052–9.
31. Hartling L, Hamm MP, Fernandes RM, Dryden DM, Vandermeer B. Quantifying bias in randomized controlled trials in child health: a meta-epidemiological study. *PloS One*. 2014;9(2):e88008.
32. Boutron I, Page MJ, Higgins JPT, Altman DG, Lundh A, Hróbjartsson A. Chapter 7: Considering bias and conflicts of interest among the included studies. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). *Cochrane Handbook for Systematic Reviews of Interventions* version 6.0 (updated July 2019) [Internet]. Cochrane. 2019 [cited 2019 Oct 22]. Available from: www.training.cochrane.org/handbook
33. Cumpston M, Li T, Page MJ, Chandler J, Welch VA, Higgins JP, et al. Updated guidance for trusted systematic reviews: a new edition of the *Cochrane Handbook for Systematic Reviews of Interventions*. *Cochrane Database Syst Rev* [Internet]. 2019 [cited 2020 Oct 21];(10). Available from: <https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.ED000142/full>
34. Tierney JF, Stewart LA. Investigating patient exclusion bias in meta-analysis. *Int J Epidemiol*. 2005 Feb;34(1):79–87.
35. Pildal J, Hróbjartsson A, Jørgensen KJ, Hilden J, Altman DG, Gøtzsche PC. Impact of allocation concealment on conclusions drawn from meta-analyses of randomized trials. *Int J Epidemiol*. 2007 Aug;36(4):847–57.
36. Nüesch E, Trelle S, Reichenbach S, Rutjes AWS, Bürgi E, Scherer M, et al. The effects of excluding patients from the analysis in randomised controlled trials: meta-epidemiological study. *BMJ*. 2009 Sep 7;339:b3244.
37. Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher M, et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses? *Lancet Lond Engl*. 1998 Aug 22;352(9128):609–13.
38. Sterne JA, Egger M, Smith GD. Systematic reviews in health care: Investigating and dealing with publication and other biases in meta-analysis. *BMJ*. 2001 Jul 14;323(7304):101–5.
39. Sterne JA, Gavaghan D, Egger M. Publication and related bias in meta-analysis: power of statistical tests and prevalence in the literature. *J Clin Epidemiol*. 2000 Nov;53(11):1119–29.
40. Sterne JAC, Sutton AJ, Ioannidis JPA, Terrin N, Jones DR, Lau J, et al. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. *BMJ*. 2011 Jul 22;343:d4002.
41. Dechartres A, Trinquart L, Boutron I, Ravaud P. Influence of trial sample size on treatment effect estimates: meta-epidemiological study. *BMJ*. 2013 Apr 24;346:f2304.
42. Jüni P, Altman DG, Egger M. Systematic reviews in health care: Assessing the quality of controlled clinical trials. *BMJ*. 2001 Jul 7;323(7303):42–6.

43. Ridgeon EE, Young PJ, Bellomo R, Mucchetti M, Lembo R, Landoni G. The Fragility Index in Multicenter Randomized Controlled Critical Care Trials. *Crit Care Med*. 2016 Jul;44(7):1278–84.
44. Anand R, Norrie J, Bradley JM, McAuley DF, Clarke M. Fool's gold? Why blinded trials are not always best. *BMJ*. 2020 21;368:16228.
45. Cohen J, Guyatt G, Bernard GR, Calandra T, Cook D, Elbourne D, et al. New strategies for clinical trials in patients with sepsis and septic shock. *Crit Care Med*. 2001 Apr;29(4):880–6.
46. Kerever S, Jacquens A, Smail-Faugeron V, Gayat E, Resche-Rigon M. Methodological management of end-of-life decision data in intensive care studies: A systematic review of 178 randomized control trials published in seven major journals. *PLOS ONE*. 2019 May 28;14(5):e0217134.
47. Schulz KF, Altman DG, Moher D. CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials. *BMJ*. 2010 Mar 24;340:c332.
48. Deeks JJ, Higgins JPT, Altman DG (editors). Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors) [Internet]. *Cochrane*. 2019 [cited 2019 Oct 22]. Available from: www.training.cochrane.org/handbook
49. Alhazzani W, Alshahrani M, Jaeschke R, Forel JM, Papazian L, Sevransky J, et al. Neuromuscular blocking agents in acute respiratory distress syndrome: a systematic review and meta-analysis of randomized controlled trials. *Crit Care Lond Engl*. 2013 Mar 11;17(2):R43.
50. Allingstrup M, Wetterslev J, Ravn FB, Moller AM, Afshari A. Antithrombin III for critically ill patients. *Cochrane Database Syst Rev*. 2016 Feb 8;2:CD005370.
51. Barbateskovic M, Marker S, Granholm A, Anthon CT, Krag M, Jakobsen JC, et al. Stress ulcer prophylaxis with proton pump inhibitors or histamin-2 receptor antagonists in adult intensive care patients: a systematic review with meta-analysis and trial sequential analysis. *Intensive Care Med*. 2019 Feb;45(2):143–58.
52. Bo L, Wang F, Zhu J, Li J, Deng X. Granulocyte-colony stimulating factor (G-CSF) and granulocyte-macrophage colony stimulating factor (GM-CSF) for sepsis: a meta-analysis. *Crit Care Lond Engl*. 2011;15(1):R58.
53. Chu DK, Kim LH-Y, Young PJ, Zamiri N, Almenawer SA, Jaeschke R, et al. Mortality and morbidity in acutely ill adults treated with liberal versus conservative oxygen therapy (IOTA): a systematic review and meta-analysis. *Lancet Lond Engl*. 2018 Apr 28;391(10131):1693–705.
54. Cortegiani A, Russotto V, Maggiore A, Attanasio M, Naro AR, Raineri SM, et al. Antifungal agents for preventing fungal infections in non-neutropenic critically ill patients. *Cochrane Database Syst Rev*. 2016 Jan 16;(1):CD004920.
55. Drewry AM, Ablordeppey EA, Murray ET, Stoll CRT, Izadi SR, Dalton CM, et al. Antipyretic Therapy in Critically Ill Septic Patients: A Systematic Review and Meta-Analysis. *Crit Care Med*. 2017 May;45(5):806–13.
56. Dushianthan A, Cusack R, Burgess VA, Grocott MP, Calder PC. Immunonutrition for acute respiratory distress syndrome (ARDS) in adults. *Cochrane Database Syst Rev*. 2019 Jan 24;1:CD012041.

57. Fujii T, Ganeko R, Kataoka Y, Furukawa TA, Featherstone R, Doi K, et al. Polymyxin B-immobilized hemoperfusion and mortality in critically ill adult patients with sepsis/septic shock: a systematic review with meta-analysis and trial sequential analysis. *Intensive Care Med.* 2018 Feb;44(2):167–78.
58. Gebistorf F, Karam O, Wetterslev J, Afshari A. Inhaled nitric oxide for acute respiratory distress syndrome (ARDS) in children and adults. *Cochrane Database Syst Rev.* 2016 Jun 27;(6):CD002787.
59. Hua F, Xie H, Worthington HV, Furness S, Zhang Q, Li C. Oral hygiene care for critically ill patients to prevent ventilator-associated pneumonia. *Cochrane Database Syst Rev.* 2016 Oct 25;10:CD008367.
60. Koster G, Bekema HJ, Wetterslev J, Gluud C, Keus F, van der Horst ICC. Milrinone for cardiac dysfunction in critically ill adult patients: a systematic review of randomised clinical trials with meta-analysis and trial sequential analysis. *Intensive Care Med.* 2016 Sep;42(9):1322–35.
61. Koster G, Wetterslev J, Gluud C, Zijlstra JG, Scheeren TWL, van der Horst ICC, et al. Effects of levosimendan for low cardiac output syndrome in critically ill patients: systematic review with meta-analysis and trial sequential analysis. *Intensive Care Med.* 2015 Feb;41(2):203–21.
62. Tao K-M, Li X-Q, Yang L-Q, Yu W-F, Lu Z-J, Sun Y-M, et al. Glutamine supplementation for critically ill adults. *Cochrane Database Syst Rev.* 2014 Sep 9;(9):CD010050.
63. Lewis K, Alqahtani Z, McIntyre L, Almenawer S, Alshamsi F, Rhodes A, et al. The efficacy and safety of prokinetic agents in critically ill patients receiving enteral nutrition: a systematic review and meta-analysis of randomized trials. *Crit Care Lond Engl.* 2016 Aug 15;20(1):259.
64. Lewis SR, Pritchard MW, Evans DJ, Butler AR, Alderson P, Smith AF, et al. Colloids versus crystalloids for fluid resuscitation in critically ill people. *Cochrane Database Syst Rev.* 2018 Aug 3;8:CD000567.
65. Liberati A, D'Amico R, Pifferi S, Torri V, Brazzi L, Parmelli E. Antibiotic prophylaxis to reduce respiratory tract infections and mortality in adults receiving intensive care. *Cochrane Database Syst Rev.* 2009 Oct 7;(4):CD000022.
66. Manzanares W, Dhaliwal R, Jurewitsch B, Stapleton RD, Jeejeebhoy KN, Heyland DK. Alternative lipid emulsions in the critically ill: a systematic review of the evidence. *Intensive Care Med.* 2013 Oct;39(10):1683–94.
67. Manzanares W, Lemieux M, Elke G, Langlois PL, Bloos F, Heyland DK. High-dose intravenous selenium does not improve clinical outcomes in the critically ill: a systematic review and meta-analysis. *Crit Care Lond Engl.* 2016 Oct 28;20(1):356.
68. Manzanares W, Lemieux M, Langlois PL, Wischmeyer PE. Probiotic and synbiotic therapy in critical illness: a systematic review and meta-analysis. *Crit Care Lond Engl.* 2016 Aug 19;19:262.
69. McIntyre WF, Um KJ, Alhazzani W, Lengyel AP, Hajjar L, Gordon AC, et al. Association of Vasopressin Plus Catecholamine Vasopressors vs Catecholamines Alone With Atrial Fibrillation in Patients With Distributive Shock: A Systematic Review and Meta-analysis. *JAMA.* 2018 May 8;319(18):1889–900.

70. Mesgarpour B, Heidinger BH, Roth D, Schmitz S, Walsh CD, Herkner H. Harms of off-label erythropoiesis-stimulating agents for critically ill people. *Cochrane Database Syst Rev*. 2017 Aug 25;8:CD010969.
71. Oczkowski SJW, Duan EH, Groen A, Warren D, Cook DJ. The Use of Bowel Protocols in Critically Ill Adult Patients: A Systematic Review and Meta-Analysis. *Crit Care Med*. 2017 Jul;45(7):e718–26.
72. Putzu A, Daems A-M, Lopez-Delgado JC, Giordano VF, Landoni G. The Effect of Vitamin C on Clinical Outcome in Critically Ill Patients: A Systematic Review With Meta-Analysis of Randomized Controlled Trials. *Crit Care Med*. 2019 Feb 26;
73. Qiu P, Cui X, Sun J, Welsh J, Natanson C, Eichacker PQ. Antitumor necrosis factor therapy is associated with improved survival in clinical sepsis trials: a meta-analysis. *Crit Care Med*. 2013 Oct;41(10):2419–29.
74. Rochweg B, Oczkowski SJ, Siemieniuk RAC, Agoritsas T, Belley-Cote E, D’Aragon F, et al. Corticosteroids in Sepsis: An Updated Systematic Review and Meta-Analysis. *Crit Care Med*. 2018 Sep;46(9):1411–20.
75. Shah A, Roy NB, McKechnie S, Doree C, Fisher SA, Stanworth SJ. Iron supplementation to treat anaemia in adult critical care patients: a systematic review and meta-analysis. *Crit Care Lond Engl*. 2016 Sep 29;20(1):306.
76. Szakmany T, Hauser B, Radermacher P. N-acetylcysteine for sepsis and systemic inflammatory response in adults. *Cochrane Database Syst Rev*. 2012 Sep 12;(9):CD006616.
77. Tan JA, Ho KM. Use of dexmedetomidine as a sedative and analgesic agent in critically ill adult patients: a meta-analysis. *Intensive Care Med*. 2010 Jun;36(6):926–39.
78. Wang JG, Belley-Cote E, Burry L, Duffett M, Karachi T, Perri D, et al. Clonidine for sedation in the critically ill: a systematic review and meta-analysis. *Crit Care Lond Engl*. 2017 Feb 25;21(1):75.
79. Zampieri FG, Nassar APJ, Gusmao-Flores D, Taniguchi LU, Torres A, Ranzani OT. Nebulized antibiotics for ventilator-associated pneumonia: a systematic review and meta-analysis. *Crit Care Lond Engl*. 2015 Apr 7;19:150.
80. Zarychanski R, Abou-Setta AM, Kanji S, Turgeon AF, Kumar A, Houston DS, et al. The efficacy and safety of heparin in patients with sepsis: a systematic review and metaanalysis. *Crit Care Med*. 2015 Mar;43(3):511–8.

FIGURE LEGENDS

Figure 1: Flow chart of the selection of reviews.

Figure 2: Comparison of intervention effects between blinded and non-blinded randomized controlled trials in eligible critical-care meta-analyses.

Figure 3: Sensitivity analyses adjusted on sample size and each item of the risk of bias tool.

Supplemental Digital Content – Figure 1: Comparison of intervention effects between randomized controlled trials judged at low risk and high or unclear risk for blinding of participants and personnel in eligible critical-care meta-analyses.

LIST OF ABBREVIATIONS

CI: Confidence Interval

ICU: Intensive Care Unit

IF: Impact Factor

IQR: Interquartile range

OR: Odds Ratio

RCT: Randomized Controlled Trial

RoB : Risk of Bias

ROR: Ratio of Odds Ratio